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Objective. SSc is characterized by microvascular abnormalities and leucocyte infiltration. Previous studies have suggested a proadhesive
phenotype in SSc skin, but the functional consequences of this phenotype are not fully understood. Molecules known to mediate leucocyte
adhesion include those present at intracellular junctions, such as junctional adhesion molecule-B (JAM-B), JAM-C and CD99, as well as
intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1). The aim of this study was to examine adhesive
interactions in SSc skin.
Methods. The expression of JAM-B, JAM-C, CD99, ICAM-1 and VCAM-1 in SSc skin was determined by immunohistology and cell surface
ELISA. Myeloid U937 cell–SSc dermal fibroblast adhesion assays or in situ adhesion assays to SSc skin were performed.
Results. JAM-C and CD99 expression on endothelial cells (ECs) in SSc skin was decreased compared with expression on normal ECs.
CD99 was overexpressed on mononuclear cells in SSc skin and on SSc dermal fibroblasts. Neutralizing ICAM-1 inhibited the binding of U937
cells to SSc dermal fibroblasts. In addition, blocking both ICAM-1 and VCAM-1 inhibited U937 cell adhesion to either proximal (less involved)
or distal (more involved) SSc skin.
Conclusions. These studies show that JAM-C and CD99 are aberrantly expressed in SSc skin. However, these adhesion molecules do not
mediate myeloid cell–SSc skin adhesion. In contrast, we demonstrate an important role for ICAM-1 and VCAM-1 in the retention of myeloid
cells in SSc skin, suggesting that targeting these molecules may be useful SSc therapies.
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Introduction
SSc or scleroderma is a multisystem disorder characterized by
RP, vasculopathy and fibrosis of the skin and internal organs.
Patients with SSc have decreased numbers of capillaries, capillary
haemorrhages and clusters of enlarged, distorted, capillary loops
that can be seen in the skin fold of the fingernails and which
correlate with sclerodermatous involvement of the skin and inter-
nal organs [1, 2]. Endothelial cells (ECs), monocytes and fibro-
blasts are among key players in the pathogenesis of SSc.
Previous studies have suggested that cellular adhesion mole-
cules may play a role in SSc pathogenesis. Serum levels of several
soluble adhesion molecules are increased in SSc compared with
healthy controls [3]. Serum levels of soluble E-selectin, vascular
cell adhesion molecule-1 (VCAM-1) and intercellular adhesion
molecule-1 (ICAM-1) correlate with SSc disease severity [4–6].
Moreover, the levels of soluble E-selectin and VCAM-1 in SSc
serum correlate with a positive response to some therapies [7, 8].
In addition to increased levels of soluble adhesion molecules in
SSc serum, we and others have shown that several adhesion mole-
cules are overexpressed in SSc skin and on SSc dermal fibroblasts.
These include VCAM-1, ICAM-1, P-selectin, E-selectin, CD44
and integrins 1, 2 and 6 [9–12]. Aberrant adhesion molecule
expression may play multiple roles in SSc pathogenesis. The
increased expression of specific adhesion molecules may lead to
increased accumulation of leucocytes in SSc skin [13, 14].
Abraham et al. [13] demonstrated that SSc fibroblasts have a
greater propensity for binding T lymphocytes compared with
normal fibroblasts, in part by their overexpression of ICAM-1.
Overexpression of selected adhesion molecules resulting in the
accumulation of specific, activated leucocytes may play a role in
the induction of fibrosis via cytokine release leading to excess
extracellular matrix synthesis [15]. Alternatively, the accumulation
of leucocytes caused by increased adhesion molecule expression,
and subsequent angiogenic/angiostatic cytokine release, may play
a role in the disorganized angiogenesis in SSc skin.
We hypothesized that adhesion molecules that are over-
expressed in SSc skin may play a role in SSc pathogenesis by
promoting the adhesion of monocytes. We first sought to deter-
mine the expression of adhesion molecules in SSc skin. These
molecules include junctional adhesion molecule-B (JAM-B),
JAM-C and CD99, which have previously been shown to play
a role in leucocyte adhesion and trans-endothelial migration
[16, 17]. We then determined which adhesion molecules mediate
myeloid cell adhesion to SSc skin. Our results demonstrate an
important role for ICAM-1 and VCAM-1 in the retention of
myeloid cells in SSc skin.
Materials and methods
Patients and controls
Punch biopsy skin samples (4mm) were obtained from 21 subjects
with SSc (all with active, diffuse disease) and 10 control subjects.
Two biopsies were taken from SSc patients, one from the proximal
arm (less clinically involved) and the other from the distal forearm
(more clinically involved). One biopsy was taken from the forearm
of healthy control subjects. All SSc patients fulfilled the ACR
criteria for classification of SSc and also met the criteria for dif-
fuse SSc [18]. Biopsies were taken with informed consent, and this
study was approved by the University of Michigan Institutional
Review Board.
Cell culture
Normal and SSc dermal fibroblast cell lines were established
as described previously [19]. All SSc fibroblasts were obtained
from untreated patients with diffuse cutaneous SSc of
1Department of Internal Medicine, University of Michigan Medical School, Ann
Arbor, MI, 2Jefferson Institute of Molecular Medicine, Thomas Jefferson
University, Philadelphia, PA, 3Department of Pathology, Yale University, New
Haven, CT and 4Department of Veterans Affairs, VA Medical Service, Ann
Arbor, MI, USA.
Submitted 3 November 2008; revised version accepted 20 March 2009.
Correspondence to: Bradley J. Rabquer, 109 Zina Pitcher Drive, 4418 BSRB,
Ann Arbor, MI 48109-2200, USA. E-mail: brabquer@med.umich.edu
*Bradley J. Rabquer and Yong Hou contributed equally to this work.
Rheumatology 2009;48:734–740 doi:10.1093/rheumatology/kep091
Advance Access publication 13 May 2009
734












recent onset. The cells were cultured in Roswell Park Memorial
Institute (RPMI) 1640 supplemented with 10% fetal bovine serum
(FBS) at 378C in a humidified atmosphere with 5% CO2. Cells
were used at passages 5–15, at which time they were a homoge-
neous, 85–95% confluent population of fibroblasts. U937 cells
(human monocytic lymphoma cell line) were cultured in RPMI
supplemented with 10% FBS at 378C in a humidified atmosphere
with 5% CO2.
Antibodies and reagents
Recombinant human TNF-, IFN-, IL-1, IL-17, IL-18, mouse
anti-human VCAM-1, mouse anti-human ICAM-1, goat anti-
human JAM-B and JAM-C antibodies were purchased from
R&D Systems (MN, USA). Mouse anti-human CD99 antibody
was purchased from Abcam Inc. (Cambridge, MA, USA).
Neutralizing rat anti-mouse/human JAM-C antibody (F26) that
was previously shown to recognize human JAM-C was used in
fibroblast adhesion assays [20]. IgG controls were purchased
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA).
Secondary antibodies were obtained from Molecular Probes Inc.
(Eugene, OR, USA).
Immunohistology
Frozen samples obtained from proximal and distal SSc skin and
normal skin were cut (5m) and stained using an immunoper-
oxidase method. Slides were fixed in cold acetone for 10min.
Following incubation with 3% H2O2 for 5min to block endogen-
ous peroxidase, the samples were incubated with 10% horse serum
in phosphate-buffered saline (PBS) at 378C for 1 h, and then
incubated with primary antibody against JAM-B, JAM-C or
CD99 (each 10g/ml) or purified non-specific IgG for 1 h at
room temperature in blocking buffer. The skin samples were
washed with PBS, and a 1 : 100 dilution (in blocking buffer) of
biotinylated secondary antibody was added and incubated for an
additional 1 h at room temperature. After washing, the antibody
binding was detected using Vectastain ABC Elite kit (Vector Labs,
Burlingame, CA, USA) and the chromogen 3,30-diaminobenzidine
(DAB) (Vector Labs). Skin samples were counterstained with
Gill’s haematoxylin. Staining was evaluated under blinded
conditions and graded by a pathologist. Slides were examined
for cellular immunoreactivity and cell types were distinguished
based on their characteristic morphology.
Cell surface ELISA
SSc and normal fibroblasts (1 104/well) were seeded in 96-well
plates (BD Falcon, Bedford, MA, USA). Upon reaching conflu-
ence, the fibroblasts were incubated with or without TNF-,
IL-1, IFN-, IL-17 or IL-18 (each 25 ng/ml) for 24 h in serum-
free media. Cells were fixed with 3.7% formalin in PBS and cell
surface ELISAs were performed as previously described [21].
Antibodies specific for JAM-B, JAM-C, CD99, ICAM-1 or
VCAM-1 (each 10mg/ml) were used, and the plates were read
with an ELISA reader (Bio-Rad, Hercules, CA, USA) at 450 nM.
In vitro cell adhesion assay
Adhesion of U937 cells to SSc fibroblasts grown to confluence in
96-well plates was tested. SSc dermal fibroblasts were serum
starved overnight, and 1 h prior to assay, the fibroblasts
were pre-incubated with neutralizing antibodies against either
JAM-B, JAM-C, CD99, ICAM-1 or irrelevant IgG controls
(each 25g/ml). The cells were collected and labelled with
calcein-AM fluorescent dye (5M; Invitrogen, Carlsbad, CA,
USA) for 20min. After washing twice, 1 105 cells were added
to each well and incubated for 20min at 378C. At the end of the
assay, non-adherent cells were washed off and fluorescence was
measured using a Synergy HT fluorescence plate reader (Bio-Tek
Instruments, Winooski, VT, USA). The inhibitory effect of each
antibody was given as the percentage of maximal binding, which
was defined as the number of adherent cells in the control anti-
body-treated sections.
Stamper–Woodruff assay
In situ adhesion assays were performed as previously described
[22]. Briefly, frozen SSc skin samples were cut (5m) and incu-
bated with neutralizing antibodies against ICAM-1, VCAM-1,
a combination of the two antibodies or irrelevant IgG control.
U937 cells were labelled with calcein-AM fluorescent dye (5M,
Invitrogen) for 20min. After incubation, medium was removed
and 1 105 fluorescent-labelled U937 cells were added to all
sections and the sections were incubated for 1 h at room tempera-
ture. At the end of the experiment, non-adherent cells were
washed off. Fluorescent U937 cell adhesion to SSc skin was
counted blindly using a BX51 Fluorescence Microscope System
and DP Manager imaging software (Olympus America, Melville,
NY, USA). The inhibitory effect of each antibody was given as the
percentage of maximal binding, which was defined as the number
of adherent cells in the control antibody-treated sections.
Statistical analysis
Data were analysed using Student’s t-test assuming equal var-
iances. P-values <0.05 were considered statistically significant.
Data are represented as the mean  S.E.M.
Results
Immunohistochemical analysis of JAM-B, JAM-C and
CD99 in SSc skin
Previous studies have suggested a proadhesive phenotype in
SSc skin. We hypothesized that adhesion molecules that are
overexpressed in SSc skin may play a role in SSc pathogenesis
by promoting the adhesion of monocytes. We first sought to deter-
mine the expression of intracellular adhesion molecules, such as
JAM-B, JAM-C and CD99, in SSc skin by immunohistochemis-
try. SSc adhesion molecule expression was determined in both
proximal (clinically less involved) and distal (clinically more
involved) skin [23]. The expression of each adhesion molecule
on specific cell types, including ECs, mononuclear cells, and in
the epidermis, was determined by a pathologist in a blinded
manner. Our results indicated that JAM-B and JAM-C were
mainly expressed on dermal ECs in normal and SSc skin
(Fig. 1). However, while JAM-B expression on dermal ECs was
conserved between normal, proximal and distal SSc skin, JAM-C
expression on dermal ECs was decreased on proximal and distal
SSc skin compared with normal skin (Fig. 1B).
Similarly, CD99 expression on proximal and distal SSc skin was
decreased compared with normal skin (Fig. 1C). However, CD99
expression was found on dermal ECs, on perivascular and sub-
epidermal mononuclear cells, and in the stratum spinosum of the
epidermis. CD99 expression in the stratum spinosum was
unchanged between normal, proximal and distal SSc skin (data
not shown). In contrast, the expression of CD99 was increased on
both perivascular and subepidermal mononuclear cells in proxi-
mal and distal SSc skin compared with normal skin (Fig. 2).
Adhesion molecule expression on SSc dermal fibroblasts
Previous studies have demonstrated that SSc dermal fibroblasts
have an increased expression of select adhesion molecules. Cell
surface ELISAs were performed to determine the expression of
JAM-B, JAM-C, CD99, ICAM-1 and VCAM-1 on normal and
SSc dermal fibroblasts. In addition, we tested whether cytokines
that are overexpressed in SSc skin and serum are able to regulate
the expression of these adhesion molecules on SSc dermal fibro-
blasts. Our findings indicate that JAM-B and JAM-C were












expressed on both normal and SSc dermal fibroblasts (Fig. 3).
However, their expression was not inducible by TNF-, IL-1
or IFN- (data not shown). In contrast to these adhesion mole-
cules, we found that CD99 expression was significantly increased
on SSc dermal fibroblasts compared with normal dermal fibro-
blasts (Fig. 3). However, as with JAM-B and JAM-C, CD99
expression was not inducible by stimulation with TNF-, IL-1
or IFN-.
Previous studies have shown that ICAM-1 and VCAM-1 are
overexpressed in SSc skin and serum [4–6, 9, 11]. We found that
the basal level of VCAM-1 expressed was low on SSc dermal
fibroblasts (Fig. 4). However, its expression was highly inducible
by TNF-, in a dose-dependent fashion. In addition, we found
that ICAM-1 was expressed on SSc dermal fibroblasts and that its
expression was inducible by stimulation with TNF-, IL-1 or
IFN-, consistent with previous findings (Fig. 4) [9]. Our results
also showed that ICAM-1 expression on SSc dermal fibroblasts
was inducible by IL-17 in a dose-dependent manner.
Adhesion molecule-mediated myeloid–SSc skin adhesion
The functional consequence of adhesion molecule expression in
SSc skin has not been thoroughly investigated. We performed
myeloid cell–SSc dermal fibroblast adhesion assays to determine
whether JAM-B, JAM-C or CD99 play a role in myeloid cell
adhesion to SSc dermal fibroblasts. Our results indicate that
these adhesion molecules do not mediate myeloid cell adhesion
to SSc dermal fibroblasts (Fig. 5). However, neutralizing
anti-ICAM-1 antibody significantly inhibited U937 cell binding
to SSc dermal fibroblasts (Fig. 5). These results suggest that
ICAM-1 is important in myeloid cell–SSc dermal fibroblast
adhesion.
We also sought to determine whether, in addition to mediating
myeloid–fibroblast adhesion, ICAM-1 mediates myeloid cell
adhesion to SSc skin. In situ adhesion assays were performed
using frozen proximal and distal SSc skin sections and U937
cells. Our results indicate that a neutralizing anti-ICAM-1 anti-
body significantly inhibits U937 cell binging to both proximal and
distal SSc skin (Fig. 6). In addition, we found that a neutralizing
anti-VCAM-1 and the combination of ICAM-1 and VCAM-1
significantly inhibits U937 cell binding to both proximal and
distal SSc skin. These results demonstrate that ICAM-1 and
VCAM-1 play a role in myeloid cell adhesion to SSc skin.
























































































FIG. 1. Immunohistochemical analysis of JAM-B, JAM-C and CD99 on SSc and
normal skin ECs. Frozen sections of proximal and distal SSc and normal skin were
stained for JAM-B, JAM-C and CD99. (A) JAM-B was highly expressed on normal
(95%), proximal (92%) and distal SSc (91%) ECs. (B) JAM-C expression was
decreased on proximal SSc (83%) and distal SSc (85%) ECs compared with
normal ECs (95%). (C) CD99 expression was decreased on proximal SSc (71%)
and distal SSc (78%) ECs compared with normal ECs (86%). Means are given with
the SEM. n¼number of patients. P<0.05 was considered significant.






















































































FIG. 2. Immunohistochemical analysis of CD99 on SSc and normal skin mono-
nuclear cells. Frozen sections of proximal and distal SSc and normal skin were
immunostained for CD99. (A) CD99 expression was increased on perivascular
mononuclear cells in proximal (39%) and distal (29%) SSc skin compared with
normal skin (18%). (B) CD99 expression was increased on subepidermal mono-
nuclear cells in proximal (21%) and distal (17%) SSc skin compared with normal






























FIG. 3. JAM-B, JAM-C and CD99 are expressed on SSc dermal fibroblasts. Cell
surface ELISAs were performed to determine if JAM-B, JAM-C and CD99 are
expressed on the surface of normal or SSc dermal fibroblasts. JAM-B, JAM-C
and CD99 are present on the surface of both normal and SSc dermal fibroblasts.
CD99 expression was significantly greater on SSc dermal fibroblasts compared
with normal. MeansSEM are shown. n¼number of patient-derived fibroblast
lines.




















































































FIG. 5. ICAM-1 mediates adhesion of U937 cells to SSc dermal fibroblasts. Adhesion assays were performed using U937 cells and SSc dermal fibroblasts in the presence
of neutralizing antibodies against ICAM-1 (A), CD99 (B), JAM-B (C) and JAM-C (D). The percent of maximal binding was defined as the number of cells adhering to the
fibroblasts in the presence of the test antibody divided by the number of adherent cells on the control-treated fibroblasts. U937 cell adhesion to SSc dermal fibroblasts was
significantly inhibited by a neutralizing antibody against ICAM-1 (92% of maximal binding). Means  SEM are shown. n ¼ the number of SSc patient-derived fibroblast lines.
P<0.05 was considered significant.















































































































































FIG. 4. The expression of VCAM-1 and ICAM-1 on SSc dermal fibroblasts is highly inducible. Cell surface ELISAs were performed to determine if VCAM-1 and ICAM-1
expression on the surface of SSc dermal fibroblasts was inducible by cytokine stimulation. (A) VCAM-1 expression on SSc dermal fibroblasts was induced by TNF-
(25 ng/ml) stimulation. (B) TNF--induced VCAM-1 expression on SSc dermal fibroblasts in a dose-dependent manner. (C) ICAM-1 expression on SSc dermal fibroblasts
was induced by TNF-, IFN-, IL-1, IL-17, but not IL-18 (each 25 ng/ml). (D) IL-17-induced ICAM-1 expression on SSc dermal fibroblasts in a dose-dependent manner.
Means  SEM are shown. n¼number of patient-derived fibroblast lines.













SSc is characterized by excessive fibrosis of the skin and internal
organs. Leucocyte infiltration occurs early in the disease process
and may contribute to both fibrosis and the vascular components
of the disease. Studies have pointed to a proadhesive phenotype in
SSc, and in particular SSc skin. We have previously shown differ-
ences in adhesion molecule expression between normal and SSc
skin [11]. P-selectin, VCAM-1 and CD44 are overexpressed on the
stratum granulosum in the SSc epidermis, while VCAM-1 is also
overexpressed on SSc dermal ECs [11]. CD44 is overexpressed on
ECs and leucocytes [11]. In addition, by demonstrating that the
expression of ICAM-1, E-selectin and integrins 1 and 2 is ele-
vated in SSc skin, Sollberg et al. [12] contributed to the idea of a
proadhesive phenotype. Moreover, the serum levels of many solu-
ble adhesion molecules in SSc serum are increased compared with
normal serum, possibly as a result of EC injury [15]. Collectively,
these studies suggest a proadhesive phenotype in SSc skin.
Adhesion molecules at intercellular junctions have many roles
that may be important in SSc skin pathogenesis. These adhesion
molecules regulate vascular permeability, leucocyte adhesion and
transmigration and, in some cases, angiogenesis. JAM-B is an
adhesion molecule expressed at the intercellular junction of ECs
[24]. It has been shown to be a key factor in a number of inflam-
matory states, as its expression is up-regulated on ECs in models
of asthma, bronchitis, interstitial nephritis and autoimmune hepa-
titis [25]. In addition, JAM-B plays a role in leucocyte adhesion
and trans-endothelial migration [17]. We found that JAM-B is















































































FIG. 6. ICAM-1 and VCAM-1 mediate adhesion of U937 cells to proximal and distal SSc skin. Stamper–Woodruff in situ assays were performed using frozen skin sections
and fluorescent-labelled U937 cells. The percent of maximal binding was defined as the number of adherent cells on the test sections divided by the number of adherent
cells on the control sections. A representative image of U937 cell binding to proximal SSc skin in the presence of an IgG isotype control (A) or anti-VCAM-1 antibody (B) is
shown. Arrows indicate U937 cells bound to SSc skin. (C) Anti-ICAM-1 antibody-inhibited U937 binding to proximal SSc skin (49% of maximal binding) and distal SSc skin
(39% of maximal binding). (D) Anti-VCAM-1 antibody-inhibited U937 binding to proximal SSc skin (59% of maximal binding) and distal SSc skin (65% of maximal binding).
(E) The combination of anti-ICAM-1 and anti-VCAM-1 antibody-inhibited U937 binding to proximal SSc skin (39% of maximal binding) and distal SSc skin (39% of maximal
binding). Magnification was  100. Means  SEM are given. n¼ the number of patients. P< 0.05 was considered significant.












highly expressed by ECs from both proximal and distal SSc skin,
at levels similar to those of ECs from normal skin. In addition, we
observed that JAM-B is expressed on both normal and SSc dermal
fibroblasts at similar levels.
Like JAM-B, JAM-C is also expressed on SSc dermal fibro-
blasts. However, in contrast to JAM-B, JAM-C expression on
dermal ECs in proximal and distal SSc skin is decreased compared
with ECs in normal skin. JAM-C is a multifunctional adhesion
molecule that mediates leucocyte adhesion and transmigration,
controls vascular permeability and plays a role in many inflam-
matory conditions [17]. However, in addition to these properties,
JAM-C has been shown to play a role in angiogenesis. Adminis-
tration of a neutralizing anti-JAM-C antibody abolishes vessel
outgrowth ex vivo [26]. Moreover, anti-JAM-C antibody treat-
ment reduces tumour growth and vascularization in vivo [26].
As EC-expressed JAM-C has been shown to be involved in both
leucocyte migration and angiogenesis, it’s down-regulation in SSc
skin could interfere with these events. However, future studies are
needed to investigate the role of JAM-C in SSc trans-endothelial
migration and angiogenesis.
In addition to these JAMs, we also evaluated the expression of
CD99. CD99 is a small, highly O-glycosylated cell surface protein
found on leucocytes and at cellular junctions between ECs [27].
This JAM also plays a critical role in monocyte trans-EC migra-
tion, and has been shown to be crucial in a number of inflamma-
tory models [16, 27, 28]. Our results are in accordance with
previous findings that indicated that CD99 is expressed on numer-
ous cell types [27]. However, we found that the expression of
CD99 is decreased on SSc dermal ECs, particularly in those of
proximal SSc skin. Reduced CD99 expression on SSc dermal ECs
may affect the migration of leucocytes through the endothelium.
However, functional studies of CD99 EC expression are needed to
elucidate the effect of diminished CD99 expression on SSc ECs.
In contrast to the expression of CD99 on SSc ECs, CD99 expres-
sion was increased on perivascular and subepidermal mononu-
clear cells and on SSc dermal fibroblasts. However, our results
indicate that while CD99 is overexpressed on SSc dermal fibro-
blasts, it is not a contributing factor to the binding of myeloid cells
to SSc dermal fibroblasts. Further studies are needed to determine
the role of altered CD99 expression in SSc skin.
Previous analysis of adhesion molecule expression in SSc
skin has demonstrated that the adhesion molecules ICAM-1 and
VCAM-1 are up-regulated in SSc skin and on SSc dermal fibro-
blasts [9, 11]. Moreover, Marlor et al. [29] demonstrated that
VCAM-1 expression is up-regulated in response to TNF- on
normal synovial and dermal fibroblasts. TNF- is a prominent
pro-inflammatory, pro-fibrotic cytokine that is elevated in SSc
serum [30]. Our results indicate that SSc dermal fibroblast
VCAM-1 expression is highly inducible by TNF- in a dose-
dependent manner. Moreover, we observed that ICAM-1 is indu-
cible by TNF-, IFN- and IL-1, as previously described [9].
In addition, we also determined whether ICAM-1 expression
was inducible by IL-17. IL-17 has previously been shown to
enhance the surface expression of ICAM-1 in normal human
dermal fibroblasts, and to be increased in the serum of patients
with SSc [31, 32]. We found that IL-17 stimulation enhanced
ICAM-1 expression on SSc dermal fibroblasts in a dose-
dependent manner. These results show that key cytokines in the
pathogenesis of SSc are able to induce the expression of VCAM-1
and ICAM-1 on SSc dermal fibroblasts.
Next, we sought to determine if the adhesion molecules
expressed in SSc skin mediate myeloid cell adhesion. Previous
studies have shown that JAM-B and JAM-C mediate leucocyte
adhesion through their interactions with the leucocyte expressed
integrins VLA-4 and Mac-1, respectively [33, 34]. In addition,
EC-expressed CD99 interacts with CD99 on the surface of neu-
trophils and monocytes to promote leucocyte adhesion [35].
However, we found that neutralizing antibodies against either
JAM-B, JAM-C or CD99 did not inhibit myeloid cell binding to
SSc dermal fibroblasts. In contrast, we observed that ICAM-1
mediates myeloid cell adhesion to SSc dermal fibroblasts.
Previously, ICAM-1 has been shown to mediate T-cell binding
to SSc dermal fibroblasts [13]. In our study, we found that
ICAM-1 not only mediates myeloid cell adhesion to SSc dermal
fibroblasts, but also myeloid cell adhesion to proximal and distal
SSc skin. Similar results were observed using a neutralizing
anti-VCAM-1 antibody. A combination of neutralizing anti-
ICAM-1 and anti-VCAM-1 antibodies resulted in augmented
inhibition of binding. Therefore, while we demonstrated a novel
role for ICAM-1 and VCAM-1 in mediating myeloid cell adhesion
in SSc skin, we did not observe a role for JAM-B, JAM-C or
CD99 in myeloid cell adhesion to SSc dermal fibroblasts or SSc
skin. It is possible that these adhesion molecules may play a role in
the adhesion of other cell types to SSc dermal fibroblasts, or that
they may facilitate adhesion between adjacent fibroblasts.
Our study was designed to determine the expression of adhesion
molecules in SSc skin and on SSc dermal fibroblasts, and to deter-
mine if they mediate myeloid cell adhesion to SSc skin. We have
shown that JAM-C and CD99 are aberrantly expressed in SSc
skin; however, we found that they do not mediate myeloid cell
adhesion to SSc dermal fibroblasts. Importantly, we demonstrated
that ICAM-1 and VCAM-1 functionally mediate myeloid cell
adhesion to SSc skin and thus potentially contribute to the bind-
ing and retention of leucocytes in sclerodermatous skin. Targeting
ICAM-1 and VCAM-1 may be useful in SSc.
Rheumatology key messages
 JAM-C and CD99 are aberrantly expressed in SSc skin.
 JAM-B, JAM-C and CD99 do not mediate myeloid cell adhesion to
SSc dermal fibroblasts.
 ICAM-1 and VCAM-1 mediate myeloid cell adhesion to SSc skin.
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